X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4773) 4773
Publication (196) 196
Book Review (9) 9
Newsletter (5) 5
Dissertation (4) 4
Book Chapter (2) 2
Newspaper Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4347) 4347
female (3649) 3649
epirubicin - administration & dosage (3402) 3402
middle aged (3101) 3101
antineoplastic combined chemotherapy protocols - therapeutic use (2707) 2707
aged (2533) 2533
oncology (2519) 2519
adult (2506) 2506
male (1886) 1886
epirubicin (1837) 1837
breast neoplasms - drug therapy (1693) 1693
chemotherapy (1613) 1613
fluorouracil - administration & dosage (1329) 1329
index medicus (1311) 1311
cyclophosphamide - administration & dosage (1275) 1275
treatment outcome (1237) 1237
antineoplastic combined chemotherapy protocols - adverse effects (1113) 1113
cancer (1046) 1046
breast cancer (946) 946
breast neoplasms - pathology (933) 933
antineoplastic combined chemotherapy protocols - administration & dosage (932) 932
cisplatin - administration & dosage (922) 922
doxorubicin (877) 877
epirubicin - adverse effects (786) 786
drug administration schedule (785) 785
chemotherapy, adjuvant (727) 727
doxorubicin - administration & dosage (692) 692
neoplasm staging (691) 691
therapy (654) 654
disease-free survival (648) 648
survival rate (615) 615
cyclophosphamide (597) 597
combined modality therapy (581) 581
antibiotics, antineoplastic - administration & dosage (573) 573
anthracyclines (548) 548
prognosis (547) 547
paclitaxel - administration & dosage (528) 528
cisplatin (522) 522
carcinoma (505) 505
survival analysis (488) 488
paclitaxel (477) 477
follow-up studies (474) 474
taxoids - administration & dosage (444) 444
epirubicin - therapeutic use (436) 436
docetaxel (431) 431
fluorouracil (426) 426
prospective studies (416) 416
survival (415) 415
pharmacology & pharmacy (409) 409
neoadjuvant therapy (404) 404
dose-response relationship, drug (402) 402
aged, 80 and over (398) 398
trial (390) 390
retrospective studies (389) 389
medicine & public health (381) 381
breast neoplasms - surgery (380) 380
care and treatment (357) 357
stomach neoplasms - drug therapy (344) 344
adenocarcinoma - drug therapy (337) 337
adjuvant chemotherapy (327) 327
breast neoplasms - mortality (325) 325
methotrexate - administration & dosage (319) 319
neoadjuvant chemotherapy (310) 310
deoxycytidine - analogs & derivatives (307) 307
surgery (306) 306
animals (303) 303
neoplasm metastasis (300) 300
time factors (292) 292
deoxycytidine - administration & dosage (286) 286
research (283) 283
etoposide - administration & dosage (282) 282
antineoplastic agents - administration & dosage (280) 280
cyclophosphamide - adverse effects (271) 271
adolescent (266) 266
5-fluorouracil (264) 264
fluorouracil - adverse effects (257) 257
vincristine - administration & dosage (256) 256
tumors (253) 253
lymphatic metastasis (248) 248
infusions, intravenous (247) 247
phase-ii (246) 246
drug therapy (244) 244
remission induction (243) 243
analysis (237) 237
carboplatin - administration & dosage (235) 235
liver neoplasms - drug therapy (231) 231
urinary bladder neoplasms - drug therapy (229) 229
lung neoplasms - drug therapy (228) 228
mitomycin - administration & dosage (228) 228
combination (227) 227
liver neoplasms - therapy (223) 223
methotrexate (220) 220
adjuvant treatment (219) 219
ifosfamide - administration & dosage (219) 219
infusions, intra-arterial (217) 217
stomach neoplasms - pathology (217) 217
randomized-trial (215) 215
capecitabine (214) 214
risk factors (209) 209
toxicity (209) 209
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4157) 4157
Japanese (321) 321
Chinese (90) 90
German (66) 66
French (49) 49
Italian (35) 35
Russian (16) 16
Spanish (15) 15
Polish (13) 13
Hungarian (9) 9
Serbian (4) 4
Bulgarian (3) 3
Danish (2) 2
Korean (2) 2
Portuguese (2) 2
Romanian (2) 2
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1175 - 1181
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 869 - 878
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
Summary Background Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 8/2008, Volume 100, Issue 15, pp. 1058 - 1067
Background Current recommendations that cancer patients receive a maximum cumulative dose of 900 mg/m2 epirubicin are based on the risk of epirubicin-mediated... 
APOPTOSIS | PHARMACOKINETICS | ONCOLOGY | CYCLOPHOSPHAMIDE | TAMOXIFEN | DOXORUBICIN | CARDIOVASCULAR-DISEASE | CARDIOTOXICITY | RADIOTHERAPY | CONGESTIVE-HEART-FAILURE | CHEMOTHERAPY | Anthracyclines - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Heart Failure - physiopathology | Antibiotics, Antineoplastic - adverse effects | Epirubicin - administration & dosage | Tamoxifen - administration & dosage | Cisplatin - administration & dosage | Fluorouracil - administration & dosage | Adult | Female | Retrospective Studies | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Heart - physiopathology | Severity of Illness Index | Disease Susceptibility | Drug Administration Schedule | Risk Factors | Proportional Hazards Models | Neoplasm Recurrence, Local - diagnosis | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Vindesine - administration & dosage | Denmark - epidemiology | Heart - drug effects | Breast Neoplasms - mortality | Methotrexate - administration & dosage | Aged | Heart Failure - chemically induced | Epirubicin - adverse effects | Breast cancer | Dosage and administration | Epirubicin | Drug therapy | Risk factors | Heart | Chemotherapy | Side effects | Toxicity | Oncology | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 10/2015, Volume 121, Issue 20, pp. 3639 - 3648
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 1/2008, Volume 100, Issue 2, pp. 121 - 133
Background Docetaxel is more effective than doxorubicin for patients with advanced breast cancer. The Breast International Group 02-98 randomized trial tested... 
CANCER PATIENTS | 1ST-LINE TREATMENT | PHASE-II TRIAL | THERAPY | EPIRUBICIN | ONCOLOGY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | METHOTREXATE | COMBINATION CHEMOTHERAPY | FLUOROURACIL | CMF | Immunohistochemistry | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Tamoxifen - administration & dosage | Receptors, Progesterone - analysis | Antineoplastic Agents, Phytogenic - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Odds Ratio | Adenocarcinoma - chemistry | Doxorubicin - administration & dosage | Drug Administration Schedule | Estrogen Receptor Modulators - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Lymphatic Metastasis | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Methotrexate - administration & dosage | Aged | Adenocarcinoma - surgery | Breast cancer | Dosage and administration | Drug therapy | Comparative analysis | Doxorubicin | Docetaxel | Clinical trials | Comparative studies | Chemotherapy | Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy... 
SURGERY | REGRESSION | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESECTION | CHEMORADIOTHERAPY | OPEN-LABEL | ESOPHAGEAL | CANCER | STOMACH | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Metastases | Confidence intervals | Infusion | Oxaliplatin | Motivation | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 13, pp. 1287 - 1295
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3786 - 3793
Purpose Data concerning the prevalence of and outcomes related to thromboembolic events (TEs) in patients with advanced gastroesophageal cancer who are... 
CISPLATIN-BASED CHEMOTHERAPY | PHASE-III TRIAL | BREAST-CANCER | FLUOROURACIL PLUS OXALIPLATIN | ONCOLOGY | ADVANCED ESOPHAGOGASTRIC CANCER | TESTICULAR CANCER | VASCULAR EVENTS | CENTRAL VENOUS CATHETERS | 1ST-LINE THERAPY | METASTATIC COLORECTAL-CANCER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Thromboembolism - chemically induced | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Thromboembolism - epidemiology | Warfarin - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Incidence | Esophageal Neoplasms - complications | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Odds Ratio | Catheterization, Central Venous - adverse effects | Stomach Neoplasms - complications | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Esophagogastric Junction - pathology | Thromboembolism - etiology | Stomach Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | United Kingdom - epidemiology | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2011, Volume 22, Issue 9, pp. 1988 - 1998
Background: Preoperative chemotherapy is a recommended treatment of both primary operable and locally advanced breast cancer. Strategies to improve efficacy... 
Neoadjuvant chemotherapy | Pathological complete response | Darbepoetin alfa | Primary breast cancer | Dose-dense chemotherapy | Dose-intensified chemotherapy | pathological complete response | primary breast cancer | COLONY-STIMULATING FACTOR | CYCLOPHOSPHAMIDE | PRIMARY SYSTEMIC TREATMENT | ADJUVANT TREATMENT | dose-intensified chemotherapy | EPOETIN-ALPHA | DOCETAXEL | COMPLETE ERADICATION | dose-dense chemotherapy | neoadjuvant chemotherapy | ONCOLOGY | INTERNATIONAL EXPERT PANEL | darbepoetin alfa | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Erythropoietin - analogs & derivatives | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Erythropoietin - administration & dosage | Polyethylene Glycols | Hemoglobins - metabolism | Paclitaxel - adverse effects | Breast Neoplasms - drug therapy | Preoperative Care | Recombinant Proteins - administration & dosage | Methotrexate - adverse effects | Breast Neoplasms - pathology | Breast Neoplasms - blood | Methotrexate - administration & dosage | Aged | Patient Compliance | Epirubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage
Journal Article